Molecular Testing for Selection of Patients With Lung Cancer for Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Guideline

被引：19
|
作者：
Rekhtman, Natasha [1 ]
Leighl, Natasha B.
Somerfield, Mark R.
机构：
[1] Amer Soc Clin Oncol, Alexandria, VA 22314 USA
来源：
JOURNAL OF ONCOLOGY PRACTICE | 2015年 / 11卷 / 02期
关键词：
D O I：
10.1200/JOP.2014.002303
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：135 / U502
页数：3
相关论文
共 50 条
  • [31] MODERN VECTOR IN TREATMENT OF PATIENTS WITH LUNG CANCER: TYROSINE KINASE INHIBITORS IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATIONS
    Smorodska, O. M.
    Moskalenko, Yu, V
    Vynnychenko, I. O.
    Vynnychenko, O., I
    Kostuchenko, V. V.
    MEDICNI PERSPEKTIVI, 2021, 26 (02): : 4 - 11
  • [32] The CAP-IASLC-AMP molecular testing guideline for the selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors.
    Ladanyi, Marc
    Cagle, Phil T.
    Beasley, Mary Beth
    Chitale, Dhananjay
    Dacic, Sanja
    Giaccone, Giuseppe
    Jenkins, Robert B.
    Kwiatkowski, David J.
    Saldivar, Juan-Sebastian
    Squire, Jeremy
    Thunnissen, Erik
    Lindeman, Neal Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Histopathologic Characteristics of Lung Adenocarcinomas With Epidermal Growth Factor Receptor Mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification
    Shim, Hyo Sup
    Lee, Da Hye
    Park, Eun Ju
    Kim, Se Hoon
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2011, 135 (10) : 1329 - 1334
  • [34] Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors
    Hsu, Hui-Te
    Yu, Chu-Chun
    Lee, Yun-Hsiang
    Chan, Jui-Chun
    Chu, Chia-Yu
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9211 - 9219
  • [35] Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors
    Hui-Te Hsu
    Chu-Chun Yu
    Yun-Hsiang Lee
    Jui-Chun Chan
    Chia-Yu Chu
    Supportive Care in Cancer, 2022, 30 : 9211 - 9219
  • [36] Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer
    Zaarour, Mazen
    Weerasinghe, Chanudi
    Nazha, Bassel
    Hassan, Samer
    Atallah, Jean-Paul
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1327 - 1336
  • [37] Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients
    Li, Jing
    Cusatis, George
    Brahmer, Julie
    Sparreboom, Alex
    Robey, Robert W.
    Bates, Susan E.
    Hidalgo, Manuel
    Baker, Sharyn D.
    CANCER BIOLOGY & THERAPY, 2007, 6 (03) : 432 - 438
  • [38] Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors
    Jaenne, Pasi A.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2006, 12 (14) : 4416S - 4420S
  • [39] Targeted Therapies for Non-Small Cell Lung Cancer: An Update on Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase Inhibitors
    Kreamer, Kristen
    Riordan, Debbie
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2015, 19 (06) : 734 - 742
  • [40] Study on the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer patients
    Chen, Fei
    Li, Hongbo
    Zhang, Huanming
    MINERVA GASTROENTEROLOGY, 2024, 70 (01): : 135 - 137
12345